Researcher
Marc BUYSE
- Keywords:Mathematics
- Disciplines:Other mathematical sciences and statistics not elsewhere classified
Affiliations
- Data Science Institute (Research institute)
Member
From1 Jun 2019 → Today - Mathematics and statistics (Department)
Member
From1 Jan 2013 → Today - Centre for Statistics (Research group)
Member
From1 Jan 1994 → Today - Faculty of Sciences (Faculty)
Member
From1 Oct 1991 → Today - Applied Mathematics (Department)
Member
From1 Oct 2001 → 31 Dec 2012 - Research Institute Center for Statistics (Research institute)
Member
From1 Oct 1994 → 31 May 2019 - Mathematics-Physics-Informatics (Division)
Member
From1 Oct 1991 → 30 Sep 2009
Publications
81 - 90 of 109
- Omics-based clinical trial designs(2013)
Authors: Marc BUYSE, Stefan Michiels
Pages: 289 - 295 - Statistical evaluation of surrogate endpoints in clinical studies(2013)
Authors: Geert MOLENBERGHS, Ariel ALONSO ABAD, Wim VAN DER ELST, Tomasz BURZYKOWSKI, Marc BUYSE
Pages: 497 - 536 - Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis(2013)
Authors: Xavier PAOLETTI, Koji Oba, Yung-Jue Bang, Harry Bleiberg, Narikazu Boku, Olivier Bouche, Nozomu Fuse, Stefan Michiels, Markus Moehler, Satoshi Morita, et al.
Pages: 1667 - 1670 - Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time(2012)
Authors: Stuart G. Baker, Daniel J. Sargent, Marc BUYSE, Tomasz BURZYKOWSKI
Pages: 248 - 257 - A statistical approach to central monitoring of data quality in clinical trials(2012)
Authors: David Venet, Erik Doffagne, Tomasz BURZYKOWSKI, Francois Beckers, Yves Tellier, Eric Genevois-Marlin, Ursula Becker, Valerie Bee, Veronique Wilson, Catherine LEGRAND, et al.
Pages: 705 - 713 - Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer(2011)
Authors: S. Gill, S. Berry, J. Biagi, C. Butts, Marc BUYSE, E. Chen, D. Jonker, C. Marginean, B. Samson, J. Stewart, et al.
Pages: S5 - S10 - Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therap...(2011)
Authors: Vicente Valero, John Forbes, Mark D. Pegram, Tadeusz Pienkowski, Wolfgang Eiermann, Gunter von Minckwitz, Henri Roche, Miguel Martin, John Crown, John R. Mackey, et al.
Pages: 149 - 156 - Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials(2011)
Authors: Qian Shi, Lindsay A. Renfro, Brian M. Bot, Tomasz BURZYKOWSKI, Marc BUYSE, Daniel J. Sargent
Pages: 2748 - 2757 - Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia(2011)
Authors: Marc BUYSE, Pierre Squifflet, Beverly J. Lange, Todd A. Alonzo, Richard A. Larson, Jonathan E. Kolitz, Stephen L. George, Clara D. Bloomfield, Sylvie Castaigne, Sylvie Chevret, et al.
Pages: 7007 - 7013 - Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission(2011)
Authors: Marc BUYSE, Stefan Michiels, Pierre Squifflet, Kathryn J. Lucchesi, Kristoffer Hellstrand, Mats L. Brune, Sylvie Castaigne, Jacob M. Rowe
Pages: 1106 - 1112